At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT-Reference-Cited by-同舟云学术

At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT

Published:2017-10-26 Issue:17 Volume:130 Page:1946-1948
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Fitzhugh Courtney D.¹²^ORCID,Cordes Stefan³^ORCID,Taylor Tiffani²,Coles Wynona²,Roskom Katherine¹,Link Mary²,Hsieh Matthew M.²^ORCID,Tisdale John F.²

Affiliation:

1. Sickle Cell Branch, National Heart, Lung, and Blood Institute (NHLBI),

2. Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases/NHLBI, and

3. Hematology Branch, NHLBI, National Institutes of Health, Bethesda, MD

Abstract

Key Points Results based on our allogeneic model suggest genetic strategies aimed at correcting at least 20% of HSCs are necessary to reverse SCD. A minority of donor myeloid cells is adequate because of the vast differences in RBC survival between donor and recipient.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/17/1946/1403016/blood772392.pdf

Reference19 articles.

1. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype;Hsieh;JAMA,2014

2. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease;Andreani;Haematologica,2011

3. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia;Walters;Biol Blood Marrow Transplant,2001

4. Nonmyeloablative stem cell transplantation with alemtuzumab/low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease;Saraf;Biol Blood Marrow Transplant,2016

5. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies;King;Am J Hematol,2015

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Auto-expansion of in vivo HDAd-transduced hematopoietic stem cells by constitutive expression of tHMGA2;Molecular Therapy - Methods & Clinical Development;2024-09

2. The Role of the Conditioning Regimen for Autologous and Ex Vivo Genetically Modified Hematopoietic Stem Cell-based Therapies: Recommendations from the ISCT Stem Cell Engineering Committee;Cytotherapy;2024-09

3. Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation;Blood Advances;2024-08-28

4. CRISPR technology in human diseases;MedComm;2024-07-29

5. Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells;Nature Communications;2024-06-11